More importantly, we have previously demonstrated a functional coupling of S1P4 with HER2, suggesting that combined treatment of cells with S1P4 antagonists and ErbB2 inhibitors might represent a more effective treatment regime for ER− breast cancer patients compared with ErbB2 inhibitors alone. This evidence concerns the gene S1PR4 and breast carcinoma.